Prosecution Insights
Last updated: November 17, 2026

Design-Zyme LLC

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Design-Zyme LLC currently maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution is centralized, involving 1 distinct examiner and 1 distinct art unit. This indicates that the company's current patent efforts are focused on a specific biological or pharmaceutical invention rather than being distributed across a range of technologies.

The busiest examiner for the portfolio is GILL, RACHEL B, who is overseeing 1 busiest examiner pending office action. Since the total number of pending office actions is also 1, this examiner is the individual currently reviewing the company's active claims. The company's immediate patent prospects are therefore tied to the specific feedback and examination style of this official.

By engaging with 1 distinct art unit, the company avoids the need to navigate the varying standards of different USPTO divisions. The 1 pending office action is the focus of the company's current prosecution strategy, allowing for a dedicated response to the examiner's findings. This concentrated profile suggests a critical phase in the development of the company's intellectual property portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GILL, RACHEL B 1 65.7% +28.6%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18499765 SELF-ADJUVANTING MULTI-PROTEIN COMPLEXES FOR MODULAR VACCINE PRODUCTION GILL, RACHEL B —

Top Art Units

Art UnitApps
1671 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18499765 SELF-ADJUVANTING MULTI-PROTEIN COMPLEXES FOR MODULAR VACCINE PRODUCTION GILL, RACHEL B 1671 §102§103§112DP Non-Final OA — Pending Nov 01, 2023

Managing Design-Zyme LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Design-Zyme LLC have?

Design-Zyme LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Design-Zyme LLC applications?

Rachel B Gill has the most, with 1 of Design-Zyme LLC's pending office actions.

What technology area are Design-Zyme LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month